A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

NCT01011998 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Withdrawn due to lack of accrual per Center DSMP, with PI concurrence

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG: Gleevec (imatinib), valproic acid

Sponsor

New Mexico Cancer Research Alliance